Atelerix

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  4. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  5. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

Related Content

Distribution

DefiniGEN and Atelerix collaborate to ship in vitro cell models without cryopreservation

The solution allows the stable distribution of sensitive samples without the need for cold chain logistics
Media

Atelerix secures Innovate UK funding for cell transport tech

The funding will support the development of room temperature technologies for shipping therapeutic cells, as part of the company’s ‘BloodReady’ project
Research & Development

Atelerix receives Innovate UK grant for cell therapy preservation hydrogel

The hydrogel tech increases shelf-life between 4°C and 25°C, increasing treatment flexibility as well as widening manufacturing options and driving down cost
Finance

ManChem funding roundup

This week has shown there is more than one way to innovate in the cutting-edge pharmaceutical realm
Subscribe now